{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:56:35Z","timestamp":1793325395923,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA270324"],"award-info":[{"award-number":["R01 CA270324"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA258204"],"award-info":[{"award-number":["R01 CA258204"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL134637"],"award-info":[{"award-number":["T32 HL134637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3NS105703"],"award-info":[{"award-number":["UG3NS105703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL134637"],"award-info":[{"award-number":["T32 HL134637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3NS105703"],"award-info":[{"award-number":["UG3NS105703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3NS105703"],"award-info":[{"award-number":["UG3NS105703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0953"],"award-info":[{"award-number":["W81XWH-22-1-0953"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910592"],"award-info":[{"award-number":["W81XWH1910592"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0604"],"award-info":[{"award-number":["W81XWH-15-1-0604"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910592"],"award-info":[{"award-number":["W81XWH1910592"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Crossing the blood\u2013brain barrier (BBB) and reaching intracranial tumours is a clinical challenge for current targeted interventions including antibody-based therapies, contributing to poor patient outcomes. Increased cell surface density of human epidermal growth factor receptor 3 (HER3) is associated with a growing number of metastatic tumour types and is observed on tumour cells that acquire resistance to a growing number of clinical targeted therapies. Here we describe the evaluation of HER3-homing nanobiological particles (nanobioparticles (NBPs)) on such tumours in preclinical models and our discovery that systemic NBPs could be found in the brain even in the absence of such tumours. Our subsequent studies described here show that HER3 is prominently associated with both mouse and human brain endothelium and with extravasation of systemic NBPs in mice and in human-derived BBB chips in contrast to non-targeted agents. In mice, systemically delivered NBPs carrying tumoricidal agents reduced the growth of intracranial triple-negative breast cancer cells, which also express HER3, with improved therapeutic profile compared to current therapies and compared to agents using traditional BBB transport routes. As HER3 associates with a growing number of metastatic tumours, the NBPs described here may offer targeted efficacy especially when such tumours localize to the brain.<\/jats:p>","DOI":"10.1038\/s41565-025-01867-7","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:14:34Z","timestamp":1740114874000},"page":"683-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth"],"prefix":"10.1038","volume":"20","author":[{"given":"Felix","family":"Alonso-Valenteen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simoun","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongQiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Taguiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Sances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelyda","family":"Gonzalez-Almeyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romny","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimngan","family":"Nguyenle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Ondatje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Benhaghnazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry B.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive N.","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Abrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-5523","authenticated-orcid":false,"given":"Lali K.","family":"Medina-Kauwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26\u201341 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1867_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/medsci5030016","volume":"5","author":"D Persaud-Sharma","year":"2017","unstructured":"Persaud-Sharma, D., Burns, J., Trangle, J. & Moulik, S. Disparities in Brain Cancer in the United States: A Literature Review of Gliomas. Medical Sciences 5, 16 (2017).","journal-title":"Medical Sciences"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"11719","DOI":"10.1073\/pnas.0604318103","volume":"103","author":"M Kinoshita","year":"2006","unstructured":"Kinoshita, M., McDannold, N., Jolesz, F. A. & Hynynen, K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood\u2013brain barrier disruption. Proc. Natl Acad. Sci. 103, 11719\u201311723 (2006).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/neuonc\/noab041","volume":"23","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol 23, 1656\u20131667 (2021). PMC8485439.","journal-title":"Neuro Oncol"},{"key":"1867_CR5","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell, J. C. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972\u20132977 (2003).","journal-title":"Cancer"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2020.06.012","volume":"489","author":"MV Babak","year":"2020","unstructured":"Babak, M. V., Zalutsky, M. R. & Balyasnikova, I. V. Heterogeneity and vascular permeability of breast cancer brain metastases. Cancer letters 489, 174\u2013181 (2020). PMC7429312.","journal-title":"Cancer letters"},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","volume":"16","author":"PR Lockman","year":"2010","unstructured":"Lockman, P. R. et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664\u20135678 (2010). PMC2999649.","journal-title":"Clin. Cancer Res."},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","volume":"91","author":"AJ Clayton","year":"2004","unstructured":"Clayton, A. J. et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91, 639\u2013643 (2004). PMC2364775.","journal-title":"Br. J. Cancer"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. New Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"New Engl. J. Med."},{"key":"1867_CR10","doi-asserted-by":"publisher","first-page":"26560","DOI":"10.18632\/oncotarget.5306","volume":"6","author":"G Palma","year":"2015","unstructured":"Palma, G. et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6, 26560\u201326574 (2015).","journal-title":"Oncotarget"},{"key":"1867_CR11","doi-asserted-by":"crossref","unstructured":"Niikura, N., Saji, S., Tokuda, Y., Iwata, H., Brain Metastases in Breast Cancer. Japanese journal of clinical oncology (2014).","DOI":"10.1093\/jjco\/hyu156"},{"key":"1867_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","volume":"124","author":"C Bailleux","year":"2021","unstructured":"Bailleux, C., Eberst, L. & Bachelot, T. Treatment strategies for breast cancer brain metastases. Br. J. Cancer 124, 142\u2013155 (2021).","journal-title":"Br. J. Cancer"},{"key":"1867_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly, D., Sendi, M. A. & Kelly, C. M. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 12, 164\u2013182 (2021). PMC7968109.","journal-title":"World J Clin Oncol"},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/djs501","volume":"105","author":"A Ocana","year":"2013","unstructured":"Ocana, A. et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 105, 266\u2013273 (2013).","journal-title":"J Natl Cancer Inst"},{"key":"1867_CR15","first-page":"355","volume":"12","author":"R Mishra","year":"2018","unstructured":"Mishra, R., Patel, H., Alanazi, S., Yuan, L. & Garrett, J. T. HER3 signaling and targeted therapy in cancer. Oncology reviews 12, 355 (2018). PMC6047885.","journal-title":"Oncology reviews"},{"key":"1867_CR16","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.3390\/cancers14246174","volume":"14","author":"MK Kilroy","year":"2022","unstructured":"Kilroy, M. K. et al. HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 14, 6174 (2022). PMC9776947.","journal-title":"Cancers"},{"key":"1867_CR17","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","volume":"27","author":"HM Haikala","year":"2021","unstructured":"Haikala, H. M. & J\u00e4nne, P. A. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Clin. Cancer Res. 27, 3528\u20133539 (2021). PMC8254743.","journal-title":"Clin. Cancer Res."},{"key":"1867_CR18","doi-asserted-by":"crossref","unstructured":"Kabraji, S., et al, Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clinical Cancer Research (2018).","DOI":"10.1158\/1078-0432.CCR-17-3351"},{"key":"1867_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2603","volume":"12","author":"L Da Silva","year":"2010","unstructured":"Da Silva, L. et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 12, R46 (2010). PMC2949633.","journal-title":"Breast Cancer Res"},{"key":"1867_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/abbs\/gmt150","volume":"46","author":"Y Lee","year":"2014","unstructured":"Lee, Y. et al. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim. Biophy. Sin. 46, 190\u2013198 (2014).","journal-title":"Acta Biochim. Biophy. Sin."},{"key":"1867_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-019-0093-1","volume":"21","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biological Procedures Online 21, 5 (2019).","journal-title":"Biological Procedures Online"},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-020-05577-7","volume":"180","author":"N Paracha","year":"2020","unstructured":"Paracha, N. et al. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane\/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat 180, 597\u2013609 (2020). PMC7103014.","journal-title":"Breast Cancer Res Treat"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","volume":"16","author":"R Soffietti","year":"2020","unstructured":"Soffietti, R., Ahluwalia, M., Lin, N. & Rud\u00e0, R. Management of brain metastases according to molecular subtypes. Nat. Rev. Neurol. 16, 557\u2013574 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/pharmaceutics12010062","volume":"12","author":"M Cavaco","year":"2020","unstructured":"Cavaco, M., Gaspar, D., Arb Castanho, M. & Neves, V. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Pharmaceutics 12, 62 (2020).","journal-title":"Pharmaceutics"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1046\/j.1471-4159.2003.02224.x","volume":"88","author":"AJ Kastin","year":"2004","unstructured":"Kastin, A. J., Akerstrom, V. & Pan, W. Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport. J. Neurochem. 88, 965\u2013970 (2004).","journal-title":"J. Neurochem."},{"key":"1867_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101643","volume":"180","author":"H Kataria","year":"2019","unstructured":"Kataria, H., Alizadeh, A. & Karimi-Abdolrezaee, S. Neuregulin-1\/ErbB network: An emerging modulator of nervous system injury and repair. Prog. Neurobiol. 180, 101643 (2019).","journal-title":"Prog. Neurobiol."},{"key":"1867_CR27","doi-asserted-by":"crossref","unstructured":"The two directions of cancer nanomedicine. Nat. Nanotechnol. (2019), 14, 1083-1083.","DOI":"10.1038\/s41565-019-0597-5"},{"key":"1867_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.003087-0","volume":"90","author":"WC Russell","year":"2009","unstructured":"Russell, W. C. Adenoviruses: update on structure and function. J. Gen. Virol. 90, 1\u201320 (2009).","journal-title":"J. Gen. Virol."},{"key":"1867_CR29","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/cancers15123240","volume":"15","author":"RL Benhaghnazar","year":"2023","unstructured":"Benhaghnazar, R. L. & Medina-Kauwe, L. Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors. Cancers 15, 3240 (2023). PMC10296971.","journal-title":"Cancers"},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/v12070718","volume":"12","author":"S Besson","year":"2020","unstructured":"Besson, S., Vragniau, C., Vassal-Stermann, E., Dagher, M. C. & Fender, P. The Adenovirus Dodecahedron: Beyond the Platonic Story. Viruses 12, 718 (2020).","journal-title":"Viruses"},{"key":"1867_CR31","doi-asserted-by":"publisher","first-page":"9747","DOI":"10.1073\/pnas.92.21.9747","volume":"92","author":"X Han","year":"1995","unstructured":"Han, X., Kasahara, N. & Kan, Y. W. Ligand-directed retroviral targeting of human breast cancer cells. PNAS 92, 9747\u20139751 (1995).","journal-title":"PNAS"},{"key":"1867_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molcel.2004.11.041","volume":"17","author":"C Zubieta","year":"2005","unstructured":"Zubieta, C., Schoehn, G., Chroboczek, J. & Cusack, S. The structure of the human adenovirus 2 penton. Mol Cell. 17, 121\u2013135 (2005).","journal-title":"Mol Cell."},{"key":"1867_CR33","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/mp200094w","volume":"8","author":"JY Hwang","year":"2011","unstructured":"Hwang, J. Y. et al. A mechanistic study of tumor-targeted corrole toxicity. Mol. Pharmaceutics 8, 2233\u20132243 (2011).","journal-title":"Mol. Pharmaceutics"},{"key":"1867_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/nnm.11.104","volume":"7","author":"H Agadjanian","year":"2012","unstructured":"Agadjanian, H. et al. Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine 7, 335\u2013352 (2012).","journal-title":"Nanomedicine"},{"key":"1867_CR35","doi-asserted-by":"publisher","first-page":"44266","DOI":"10.1074\/jbc.M105428200","volume":"276","author":"E Singer","year":"2001","unstructured":"Singer, E., Landgraf, R., Horan, T., Slamon, D. & Eisenberg, D. Identification of a Heregulin Binding Site in HER3 Extracellular Domain. J. Biol. Chem. 276, 44266\u201344274 (2001).","journal-title":"J. Biol. Chem."},{"key":"1867_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/viro.1999.9864","volume":"262","author":"SS Hong","year":"1999","unstructured":"Hong, S. S., Gay, B., Karayan, L., Dabauvalle, M. C. & Boulanger, P. Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology 262, 163\u2013177 (1999).","journal-title":"Virology"},{"key":"1867_CR37","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","volume":"3","author":"M Tanner","year":"2004","unstructured":"Tanner, M. et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Molecular Cancer Therapeutics 3, 1585\u20131592 (2004).","journal-title":"Molecular Cancer Therapeutics"},{"key":"1867_CR38","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.stemcr.2018.02.012","volume":"10","author":"S Sances","year":"2018","unstructured":"Sances, S. et al. Human iPSC-Derived Endothelial Cells and Microengineered Organ-Chip Enhance Neuronal Development. Stem cell reports 10, 1222\u20131236 (2018). PMC5998748.","journal-title":"Stem cell reports"},{"key":"1867_CR39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.stem.2017.04.002","volume":"20","author":"GD Vatine","year":"2017","unstructured":"Vatine, G. D. et al. Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier. Cell Stem Cell 20, 831\u2013843.e5 (2017). PMC6659720.","journal-title":"Cell Stem Cell"},{"key":"1867_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.stem.2019.05.011","volume":"24","author":"GD Vatine","year":"2019","unstructured":"Vatine, G. D. et al. Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications. Cell Stem Cell 24, 995\u20131005.e6 (2019).","journal-title":"Cell Stem Cell"},{"key":"1867_CR41","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1021\/mp400467x","volume":"10","author":"CH Jones","year":"2013","unstructured":"Jones, C. H., Chen, C.-K., Ravikrishnan, A., Rane, S. & Pfeifer, B. A. Overcoming Nonviral Gene Delivery Barriers: Perspective and Future. Mol. Pharmaceutics 10, 4082\u20134098 (2013).","journal-title":"Mol. Pharmaceutics"},{"key":"1867_CR42","doi-asserted-by":"publisher","first-page":"e02731","DOI":"10.1128\/mBio.02731-19","volume":"11","author":"H Salimi","year":"2020","unstructured":"Salimi, H. et al. Encephalitic Alphaviruses Exploit Caveola-Mediated Transcytosis at the Blood-Brain Barrier for Central Nervous System Entry. mBio 11, e02731\u201319 (2020). PMC7018649.","journal-title":"mBio"},{"key":"1867_CR43","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.neuron.2017.03.043","volume":"94","author":"BJ Andreone","year":"2017","unstructured":"Andreone, B. J. et al. Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis. Neuron 94, 581\u2013594.e5 (2017). PMC5474951.","journal-title":"Neuron"},{"key":"1867_CR44","doi-asserted-by":"publisher","first-page":"e0276462","DOI":"10.1371\/journal.pone.0276462","volume":"17","author":"AH Kadam","year":"2022","unstructured":"Kadam, A. H. et al. Targeting caveolae to pump bispecific antibody to TGF-\u03b2 into diseased lungs enables ultra-low dose therapeutic efficacy. PLoS One 17, e0276462 (2022).","journal-title":"PLoS One"},{"key":"1867_CR45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.omtn.2023.05.019","volume":"32","author":"C Del Toro Runzer","year":"2023","unstructured":"Del Toro Runzer, C. et al. Cellular uptake of modified mRNA occurs via caveolae-mediated endocytosis, yielding high protein expression in slow-dividing cells. Molecular Therapy - Nucleic Acids 32, 960\u2013979 (2023).","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"1867_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jinorgbio.2007.10.026","volume":"102","author":"A Haber","year":"2008","unstructured":"Haber, A., Agadjanian, H., Medina-Kauwe, L. K. & Gross, Z. Corroles that bind with high affinity to both apo and holo transferrin. J. Inorg. Biochem. 102, 446\u2013457 (2008).","journal-title":"J. Inorg. Biochem."},{"key":"1867_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/bjc.2013.757","volume":"110","author":"YH Park","year":"2014","unstructured":"Park, Y. H. et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br. J. Cancer 110, 384\u2013391 (2014).","journal-title":"Br. J. Cancer"},{"key":"1867_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2014.23","volume":"3","author":"S Tiwary","year":"2014","unstructured":"Tiwary, S. et al. ERBB3 is required for metastasis formation of melanoma cells. Oncogenesis 3, e110 (2014).","journal-title":"Oncogenesis"},{"key":"1867_CR49","doi-asserted-by":"publisher","first-page":"eaal4682","DOI":"10.1126\/scitranslmed.aal4682","volume":"9","author":"DP Kodack","year":"2017","unstructured":"Kodack, D. P. et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci. Transl. Med. 9, eaal4682 (2017). PMC5917603.","journal-title":"Sci. Transl. Med."},{"key":"1867_CR50","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.1093\/nar\/gkz900","volume":"47","author":"F Alonso-Valenteen","year":"2019","unstructured":"Alonso-Valenteen, F. et al. HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo. Nucleic Acids Res. 47, 11020\u201311043 (2019). PMC6868389.","journal-title":"Nucleic Acids Res."},{"key":"1867_CR51","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","volume":"98","author":"NA Baker","year":"2001","unstructured":"Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98, 10037\u201310041 (2001). PMC56910.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1867_CR52","doi-asserted-by":"publisher","first-page":"W665","DOI":"10.1093\/nar\/gkh381","volume":"32","author":"TJ Dolinsky","year":"2004","unstructured":"Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665\u2013W667 (2004). (Web Server issue)PMC441519.","journal-title":"Nucleic Acids Res."},{"key":"1867_CR53","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015). PMC4821407.","journal-title":"J. Chem. Theory Comput."},{"key":"1867_CR54","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case, D. A. et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668\u20131688 (2005). PMC1989667.","journal-title":"J. Comput. Chem."},{"key":"1867_CR55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cpt.742","volume":"103","author":"A Jain","year":"2018","unstructured":"Jain, A. et al. Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. Clin. Pharmacol. Ther. 103, 332\u2013340 (2018). PMC5693794.","journal-title":"Clin. Pharmacol. Ther."},{"key":"1867_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.scr.2013.01.009","volume":"10","author":"AD Ebert","year":"2013","unstructured":"Ebert, A. D. et al. EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res 10, 417\u2013427 (2013). PMC3786426.","journal-title":"Stem Cell Res"},{"key":"1867_CR57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.stemcr.2022.02.008","volume":"17","author":"D Simkin","year":"2022","unstructured":"Simkin, D. et al. Homozygous might be hemizygous: CRISPR\/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls. Stem cell reports 17, 993\u20131008 (2022).","journal-title":"Stem cell reports"},{"key":"1867_CR58","first-page":"425","volume":"28","author":"C Foltz","year":"1999","unstructured":"Foltz, C. & Ullman-Cullere, M. Guidelines for Assessing the Health and Condition of Mice. Laboratory Animal Science 28, 425\u2013532 (1999).","journal-title":"Laboratory Animal Science"},{"key":"1867_CR59","first-page":"319","volume":"49","author":"MH Ullman-Culler\u00e9","year":"1999","unstructured":"Ullman-Culler\u00e9, M. H. & Foltz, C. J. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 49, 319\u2013323 (1999).","journal-title":"Lab Anim Sci"},{"key":"1867_CR60","unstructured":"Hickman, D. L. Use of body condition scoring as an endpoint for tumor growth studies; January 31, (2006), 2006."},{"key":"1867_CR61","unstructured":"Charles River Laboratories International, I. BALB\/C Mouse Hematology. https:\/\/www.criver.com\/sites\/default\/files\/Technical%20Resources\/Clinical%20Pathology%20Data%20for%20BALB_c%20Mouse%20Colonies%20in%20North%20America%20for%20January%202008%20-%20December%202012.pdf"},{"key":"1867_CR62","unstructured":"Charles River Laboratories International, I. NU\/NU Mouse Hematology. https:\/\/r.search.yahoo.com\/_ylt=AwrO6mcyy.RkLpoOmz8PxQt.;_ylu=Y29sbwNncTEEcG9zAzIEdnRpZAMEc2VjA3Ny\/RV=2\/RE=1692744626\/RO=10\/RU=https%3a%2f%2fwww.criver.com%2fsites%2fdefault%2ffiles%2fresources%2fdoc_a%2fNUNUMouseClinicalPathologyData.pdf\/RK=2\/RS=.kKUhVCfm34lM6lL6HxPieBNMLI-"},{"key":"1867_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4161\/cc.8.3.7608","volume":"8","author":"U Del Monte","year":"2009","unstructured":"Del Monte, U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 8, 505\u2013506 (2009).","journal-title":"Cell Cycle"},{"key":"1867_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2017.12.024","volume":"271","author":"JD Sims","year":"2018","unstructured":"Sims, J. D. et al. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J. Controlled Release 271, 127\u2013138 (2018).","journal-title":"J. Controlled Release"}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-01867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-01867-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-01867-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:03:43Z","timestamp":1747843423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-01867-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1038\/s41565-025-01867-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1139650\/v1","asserted-by":"object"}]},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author L.K.M.-K. declares the following competing interests: US patents on HerDox technology, methods and uses (9078927, 9789201, 9850293, 10391180); targeted corrole technology, methods and uses (9757386); and delivery across the BBB and uses for targeting brain-localized\/brain-metastatic tumours (10183078).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}